Phase 2 Lung Cancer Trial, Recruiting NCT06947694 Sponsor: Xinqiao Hospital of Chongqing Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT06947694
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with non-small cell lung cancer, confirmed through a tissue sample test (biopsy or pathology).
  • People who have between 3 and 6 areas in the body where the cancer has spread (metastatic lesions).
  • People who either have no cancer spread to the brain, or whose brain lesions are considered stable.
  • People whose cancer has tested negative for certain gene changes, specifically in the EGFR, ALK, ROS, BRAF, MET, and RET genes.
  • People who have a good general level of physical functioning (scored 0–1 on a standard medical scale) and are expected to live for more than 3 months.
  • People aged between 18 and 75 years old.
  • People who have had, or are able to have, a type of full-body scan called a PET-CT (this is listed as preferred but not strictly required — confirm with trial site).
  • People who have no medical reasons preventing them from receiving immunotherapy or radiotherapy.
  • People who have read and signed the trial's informed consent form.

Who may not be able to join:

  • People who have serious problems with the functioning of their heart, liver, or kidneys.
  • People who have, or have had, another type of cancer in addition to their lung cancer.
  • People who have heart disease that is not well controlled, or who have had a heart attack within the past six months.
  • People who have a history of mental illness.
  • People whom the trial researchers consider unsuitable for participation for other reasons (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jianguo Sun, MD, the second affiliated hospital of Army medical university, Chongqing, Chongqing 40037 Recruiting

Phone: 023-68774490

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Xinqiao Hospital of Chongqing
Registry
ClinicalTrials.gov
Start date
2 July 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The remission rate of abscopal lesions

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov